Toggle Main Menu Toggle Search

Open Access padlockePrints

CACHE Challenge #2: Targeting the RNA Site of the SARS-CoV-2 Helicase Nsp13

Lookup NU author(s): Ayaz Ahmad, Dr Roly ArmstrongORCiD, Dr Mat Bieniek, Aaron Campbell, Dr Daniel ColeORCiD, Ben Cree, Kallie Friston, Dr Kate HarrisORCiD, Joshua Horton, Dr Rachael Pirie, Natalie Roper, Dr Natalie TatumORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

A critical assessment of computational hit-finding experiments (CACHE) challenge was conducted to predict ligands for the SARS-CoV-2 Nsp13 helicase RNA binding site, a highly conserved COVID-19 target. Twenty-three participating teams comprised of computational chemists and data scientists used protein structure and data from fragment-screening paired with advanced computational and machine learning methods to each predict up to 100 inhibitory ligands. Across all teams, 1957 compounds were predicted and were subsequently procured from commercial catalogs for biophysical assays. Of these compounds, 0.7% were confirmed to bind to Nsp13 in a surface plasmon resonance assay. The six best-performing computational workflows used fragment growing, active learning, or conventional virtual screening with and without complementary deep-learning scoring functions. Follow-up functional assays resulted in identification of two compound scaffolds that bound Nsp13 with a Kd below 10 μM and inhibited in vitro helicase activity. Overall, CACHE #2 participants were successful in identifying hit compound scaffolds targeting Nsp13, a central component of the coronavirus replication-transcription complex. Computational design strategies recurrently successful across the first two CACHE challenges include linking or growing docked or crystallized fragments and docking small and diverse libraries to train ultrafast machine-learning models. The CACHE #2 competition reveals how crowd-sourcing ligand prediction efforts using a distinct array of approaches followed with critical biophysical assays can result in novel lead compounds to advance drug discovery efforts.


Publication metadata

Author(s): Herasymenko O, Silva M, Abu-Saleh AA, Ahmad A, Alvarado-Huayhuaz J, Arce OEA, Armstrong RJ, Arrowsmith C, Bachta KE, Beck H, Berta D, Bieniek MK, Blay V, Bolotokova A, Bourne PE, Breznik M, Brown PJ, Campbell ADG, Carosati E, Chau I, Cole DJ, Cree B, Dehaen W, Denzinger K, dos Santos Machado K, Dunn I, Durai P, Edfeldt K, Edwards A, Fayne D, Felfoldi D, Friston K, Ghiabi P, Gibson E, Guenther J, Gunnarsson A, Hillisch A, Houston DR, Halborg Jensen J, Harding RJ, Harris KS, Hoffer L, Hogner A, Horton JT, Houliston S, Hultquist JF, Hutchinson A, Irwin JJ, Jukic M, Kandwal S, Karlova A, Katis VL, Kich RP, Kireev D, Koes D, Inniss NL, Lessel U, Liu S, Loppnau P, Lu W, Martino S, McGibbon M, Meiler J, Mettu A, Money-Kyrle S, Moretti R, Moroz YS, Muvva C, Newman JA, Obendorf L, Paige B, Pandit A, Park K, Perveen S, Pirie R, Poda G, Protopopov M, Putter V, Ricci F, Roper NJ, Rosta E, Rzhetskaya M, Sabnis Y, Satchell KJF, Schmitt Kremer F, Scott T, Seitova A, Steinmann C, Talagayev V, Tarkhanova OO, Tatum NJ, Treleaven D, Velasque Werhli A, Walters WP, Wang X, Wells J, Wells G, Westermaier Y, Wolber G, Wortmann L, Zhang J, Zhao Z, Zheng S, Schapira M

Publication type: Article

Publication status: Published

Journal: Journal of Chemical Information and Modeling

Year: 2025

Volume: 65

Issue: 13

Pages: 6884-6898

Online publication date: 20/06/2025

Acceptance date: 05/06/2025

Date deposited: 11/07/2025

ISSN (print): 1549-9596

ISSN (electronic): 1549-960X

Publisher: American Chemical Society

URL: https://doi.org/10.1021/acs.jcim.5c00535

DOI: 10.1021/acs.jcim.5c00535

ePrints DOI: 10.57711/e3b2-d314


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
.Work at Northwestern University was supported by a development award from NIAID QCRG-AViDD grant 1U19AI171110-01 (to K.S. and K.B.)
CAPES Financial Code 001, FAPERGS processes 22/2551-0000385-0 and 22/25510000390-7 and CNPq grant 440363/2022-5.
EP/S022791/1EPSRC
EPSRC Centre for Doctoral Training in Molecular Sciences for Medicine (EP/S022791/1)
Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875510.
National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT) (No. RS-2024-00440975)
Newcastle/Monash University AcademicTrack (NUMAcT)Fellowship funded by Research England (ref.131911)
Open Science Drug Discovery grant from Canada’s Strategic Innovation Fund (SIF Stream 5) administered by Conscience as well as by NIH grant 1U19AI171292-01
rish Research Council (Research Ireland) under grant number GOIPG/2021/954.
WD was supported by the Ministry of Education, Youth and Sports of the Czech Republic − NationaInfrastructure for Chemical Biology (CZ-OPENSCREEN, LM2023052)l
Work at Newcastle University was funded by a UKRI Future Leaders Fellowship (MR/T019654/1)
Work at the University of Edinburgh (DRH) was supported by the Wellcome Discovery Award 227243/Z/23/Z to Bungo Akiyoshi, and the Medical Research Council research grant MR/Y013131/1
Work at University of Maribor (MJ) was supported by Slovenian Research Agency ARIS Grant No. J7-50043.
Work at Vanderbilt University (JM, RM & TS) was supported by a grant from Boehringer Ingelheim. WorkatUniversity of Pittsburgh (ID & DRK)wassupportedby R35GM140753fromNIGMS
WorkattheUniversityofOxford (VLK and JAN) was supported by the NIH grant 1U19AI171292-01 (READDI-AViDD Center)

Share